Spasticity Management in Neurological Conditions
description
Transcript of Spasticity Management in Neurological Conditions
![Page 1: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/1.jpg)
Spasticity Management in Neurological Conditions
A Quick-Start GuideGeorge F. Wittenberg MD PhD
28 January 2010
![Page 2: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/2.jpg)
Outline
• The Upper Motor Neuron Syndrome• Spasticity Management through Oral
Medications• Spasticity Management through Parenteral
Medications– Botulinum Toxins– Intrathecal Baclofen
• Emergency Management
![Page 3: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/3.jpg)
Upper Motor Neuron Syndrome
Positive Signs (Excessive normal resting state)– Spasticity– Rigidity– Hyperreflexia– Primitive reflexes– Clonus
Negative Signs (Less than normal resting state)– Lack of strength– Lack of motor control– Lack of coordination
Young RR, Emre M, Nance PW, et al. Current issues in spasticity management. Neurologist. 1997; 3:261-275.Young RR. Treatment of spastic paresis. N Engl J Med. June 1989;320(23):1553-1555.
![Page 4: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/4.jpg)
Examples of UMN Lesions
– Stroke– Multiple Sclerosis– Corticobasal Ganglionic Degeneration– Traumatic Brain Injury– Acquired Brain Injury – Spinal Cord Injury– Cerebral Palsy
![Page 5: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/5.jpg)
Pathophysiology of Spasticity
![Page 6: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/6.jpg)
Spasticity: Consequences
• Pain and discomfort• Contractures• Increased energy cost of
movement• Skin breakdown–shear• Interferes with breathing• Hampers gait and
transfers
• Interferes with hygiene• More work for caregiver• Poor safety• Sexual difficulties• Insomnia• Poor posture
![Page 7: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/7.jpg)
Spasticity: Assessment• Patient report• Deep tendon reflexes• Passive range of motion• Test for clonus• Functional observation
– Determine nature of hypertonicity– Assess interference with function (gait) and effect of stress and/or
fatigue– Assess adaptive shortening of muscles vs. irreversible contracture
• Consider aggravating factors (e.g., UTI, infection, excessive activity, strengthening exercises)
![Page 8: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/8.jpg)
Modified Ashworth Scale
0. No increase in muscle tone1. (1) Slight increase in muscle tone, manifested
by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension.
2. (1+) Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the reminder (less than half) of the ROM (range of movement).
3. (2) More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved.
4. (3) Considerable increase in muscle tone passive, movement difficult.
5. (4) Affected part(s) rigid in flexion or extension.
(Original Ashworth score in parentheses; Modified after Bohannon and Smith Phys Ther. 1987 Feb;67(2):206-7.
![Page 9: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/9.jpg)
Considerations in Reducing Spasticity
• Possible Advantages of Spasticity– Maintains muscle tone/bulk– Helps support circulatory function– May prevent formation of deep vein blood
thrombosis– May assist in activities of daily living– May assist with postural control
![Page 10: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/10.jpg)
Spasticity: Rehabilitation Intervention
•Static stretch •Gait training (emphasis on swing and heel strike)
•Positioning/posture
•Cooling•Patient education•Relaxation
•Bio-feedback•Reflex-inhibiting movement patterns
•Avoiding noxious stimuli
•Medications•ITB Therapy•Botulinum Toxin
![Page 11: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/11.jpg)
Spasticity: Medication
• Baclofen (Lioresal)– GABA agonist– Max. dose 180 mg daily, divided– Side effects: sedation, incontinence, weakness,
withdrawal seizures• Tizanidine (Zanaflex)– Alpha2 adrenergic agonist – Max. dose 24-32 mg daily– Side effects: sedation, hypotension, weakness,
hepatotoxicity • Dantrolene - reserve for specialists• Diazepam et al. (Valium)• Gabapentin (Neurontin)
![Page 12: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/12.jpg)
Considerations in Starting Oral Medications
• Titrate slowly: increase dose every five days, starting at:– 5 mg baclofen qHS– 2 mg tizanidine qHS
• Inform patients to back off to previous dose if they encounter problems with sedation, other expected effects.
• Effectiveness variable, often marginal
![Page 13: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/13.jpg)
Spasticity: Invasive ℞
• Botulinum Toxins A & B• Baclofen pump – Intrathecal delivery via implanted pump
(ITB) • Surgical interventions– Tenotomy (Tendon Lengthening)– Selective Rhizotomy
![Page 14: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/14.jpg)
Botulinum Toxins
• Derived from Clostridium botulinum bacteria• Multiple forms, but only A & B clinically approved• Produce reduction in muscle overactivity from 2-200
days after injection– Peak effect begins 7-10 days after– Should not be reinjected before 90 days– May eventually become ineffective due to antibodies
![Page 15: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/15.jpg)
Injection Procedure
QuickTime™ and a decompressor
are needed to see this picture.
•Monitor with EMG (optional)
•Allows identification of muscles
•Can help identify best targets
QuickTime™ and a decompressor
are needed to see this picture.
•Injected near motor points of muscles
•Multiple injections per muscle
![Page 16: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/16.jpg)
Common Spasticity syndromes treatable with Botulinum Toxin
• Thumb in palm – and clenched hand/flexed wrist in general
• Elbow flexion• Striatal/Clenched toes• Equinovarus deformity• Scissoring Gait
QuickTime™ and a decompressor
are needed to see this picture.
![Page 17: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/17.jpg)
Side Effects of Botulinum Toxins
• Systemic Botulism • Respiratory compromise• Dysphagia• Dry mouth• Muscle Pain• Weakness
![Page 18: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/18.jpg)
Response Problems
• Poor response may be primary (with first injection) or secondary
• Reasons for poor response– Poor muscle injection technique – Incorrenct muscle selection – Dosing inadequate – Muscle involvement has changed– Soft tissue contracture
• Neutralizing antibodies may be present (but rare in spasticity)– Tests for nonresponse: frontalis test, – antibody assays (limited sensitivity, specificity)
![Page 19: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/19.jpg)
Dosing of Botulinum Toxin
• Botox (onabotulinumtoxinA) available in 100 unit vials of lyophilized powder– Max dose not established, but FDA warns against dosing
more than 400 units• MyoBloc (rimabotulinumtoxinB) units are about 50x
less potent than Botox• So 100 units Botox are approximately equivalent to
5000 units MyoBloc
![Page 20: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/20.jpg)
ITB Therapy• Intrathecal Baclofen Therapy delivers liquid baclofen directly
into the intrathecal space around the spinal cord• Drug delivered via an implanted and programmable pump
connected to a catheter • Approved by FDA in 1992 for spinal origin spasticity and 1996
for cerebral origin spasticity.– Components are completely implanted (except the programmer)– Programmer is used to adjust the pump.– Implanting the pump is the beginning of therapy, takes 30-90 days to
adjust dosage
![Page 21: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/21.jpg)
SynchroMed II Pump
![Page 22: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/22.jpg)
Pump Compatibility• The following are unlikely to affect pump operation or damage
the pump:– Electrocautery– Diagnostic Ultrasound– Low-Power Therapeutic Ultrasound – i.e. the type used in
P.T.– Pacemakers/ICD’s– Diagnostic X-rays– TENS– Laser Procedures– Pressurized Aircraft– Theft detectors/Security Devices– Home Appliances– Tanning Bed
![Page 23: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/23.jpg)
Advantages of ITB ℞
• Non-destructive and reversible• Potential for fewer side effects as compared
to oral baclofen• Dose can be adjusted to optimal effect• May decrease spasticity-related pain
![Page 24: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/24.jpg)
Potential Risks of ITB ℞
• Most common side effects: weakness, drowsiness, nausea/vomiting, headache, and dizziness
• Overdose, although rare, could lead to respiratory depression, loss of consciousness, coma, and in extreme cases, may be life-threatening
• Infection
![Page 25: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/25.jpg)
Potential Risks of ITB ℞
• Abrupt discontinuation can result in high fever, altered mental status, worsened spasticity, and muscle rigidity– needs to be treated as life threatening
• Causes:– Empty pump reservoir– Catheter failure: disconnecting from pump, kinking,
migrating or breaking– Electromechanical failure, e.g. battery failure
![Page 26: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/26.jpg)
Management Issues: Spasticity has increased
– Patient not getting enough drug• Low reservoir• Programming/refill error• Pump or catheter problem
– Factor causing increase in spasticity• Disease progression• Physiologic response
![Page 27: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/27.jpg)
Management Issues: Spasticity has decreased – hypotonia
– Patient getting too much drug• Programming error• Refill error• Subdural catheter• Pump pocket injection• Oral medication
![Page 28: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/28.jpg)
Management Issues: Altered Mental Status
• Altered mental status– Could be sign of overdose or withdrawal• Has spasticity increased or decreased?• Other associated symptoms
![Page 29: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/29.jpg)
Circumstances That May Require Added Attention
• Higher ITB Therapy doses• Non-verbal patient• Inability to identify problem/localize pain• ITB Therapy naïve medical system– ER/ICU doesn’t contact “pump doctor”
until after cascade effect • After pump replacement• After pump removal for infection
![Page 30: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/30.jpg)
Lioresal Intrathecal
• Lioresal Intrathecal is an analog to the naturally occurring inhibitory neurotransmitter gamma-aminobutyric acid (GABA) – Effects similar to benzodiazepines
• SynchroMed® II pump reservoir holds 20 or 40 ml of drug– 6-month supply• 500 mcg/ml• 2000 mcg/ml
![Page 31: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/31.jpg)
Overdose• Symptoms Are Dose-Dependent
– Mild• Hypotonia• Difficulty concentrating• Progressive decrease in tone to flaccid
– Moderate• Somnolence• Obtundation• Bradycardia
– Severe• Stupor• Hypoventilation to apnea• Coma
![Page 32: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/32.jpg)
Overdose
• Iatrogenic– Likely due to human error– Programming error– Unanticipated effect of dosage or concentration
• SynchroMed pump vs. catheter malfunction• Difficult to ascertain cause
![Page 33: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/33.jpg)
Overdose – Mechanical Causes
• Subdural catheter• Filling of pump pocket– 18 ml of Lioresal Intrathecal 500 mcg/ml=9 mg– 18 ml of Lioresal Intrathecal 2000 mcg/ml=36 mg– 40 ml of Lioresal Intrathecal 500 mcg/ml=20 mg– 40 ml of Lioresal Intrathecal 2000 mcg/ml=80 mg
![Page 34: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/34.jpg)
Overdose - TreatmentSuggested Treatments
• Mild– Decrease dose
• Moderate– Stop pump for several hours (2-4 hours)• Program minimal infusion bolus, then restart at
lower dose– Decrease dose
• Monitor patient carefully for at least 24 hours
![Page 35: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/35.jpg)
Severe OverdoseSuggested Treatment• Maintain airway/breathing/circulation• Empty pump reservoir to stop drug flow– Aspirate reservoir if no programmer– Remember to schedule restart
• Administer physostigmine/pressors – +/- physostigmine(0.5-1.0mg increments IV)
• LP to withdraw 30 – 40 mL CSF• Notify patient's ITB Therapy physician• Continue to monitor closely for symptom recurrence
![Page 36: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/36.jpg)
Suggested Treatment
• Remove CSF– An effective treatment• Effective in first 4 hours• Still may be effective up to 8 hours
– Catheter access port (CAP)– 30 – 40 mL– Lumbar puncture if cannot aspirate CAP
![Page 37: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/37.jpg)
Sequelae of Severe Overdose
• Patient– Less frequent if airway is protected and
hypotension treated rapidly• Family– Fear of patient’s death– Fear of brain damage– Intensive emotional support needed
![Page 38: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/38.jpg)
Baclofen Withdrawal
• Severity of withdrawal varies– Mild
• Minimal symptoms • Mild flu-like syndrome
– Moderate• Increase in tone• Itching• Mild dysphoria
– Severe• Continuous spasms• Severe pain• Delirium• Death
![Page 39: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/39.jpg)
Symptoms of Underdose• Pruritis without rash• Hypotension• Paresthesias• Fever• Altered mental status
![Page 40: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/40.jpg)
Symptoms of Withdrawal
• Exaggerated rebound spasticity and muscle rigidity• Might be diagnosed in ER as seizures• Rhabdomyolysis• Multiple organ failure
May resemble• Autonomic dysreflexia• Sepsis• Malignant hyperthermia• Neuroleptic-malignant syndrome
![Page 41: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/41.jpg)
Suggested TreatmentAlways assume it’s the Intrathecal Baclofen• Initiate life-sustaining measures if indicated• Thorough history– Abrupt vs insidious onset– Presence of VPS– Recent refill/replacement/programming
• Start oral baclofen– Each patient needs prescription at home– Remind family to take prescription on vacation
![Page 42: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/42.jpg)
Other Interventions– Benzodiazepines
• GABA agonists• IV or PO
– Cyproheptadine (serotonin antagonist)*• Cyproheptadine 4-8 mg every 6 hours
– Lioresal Intrathecal via LP• 50-100 mcg bolus
– Lumbar infusion via bedside pump and percutaneous catheter• Maintenance• Weaning ITB Therapy
*Meythaler JM, Roper JF, Brunner RC. Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 2003; 84:638-642.
![Page 43: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/43.jpg)
Pearls to Prevent Withdrawal
• Refill pump if suspect low reservoir• Compare actual vs expected aspirate• Verify concentration of last refill• Systems to ensure patients receive refills in a timely
manner• Examine programming after pump replacement• Troubleshoot pump and catheter immediately upon
suspicion of malfunction• Patients should have some oral baclofen available for
emergency
![Page 44: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/44.jpg)
Conclusions
• While spasticity management can be difficult, it may also improve patient’s quality of lift
• Spasticity is not necessarily the enemy, but is part of a pattern of abnormal motor control
• Choice of treatment depends on pattern of involvement
![Page 45: Spasticity Management in Neurological Conditions](https://reader031.fdocuments.net/reader031/viewer/2022013114/5481f2ffb07959240c8b4674/html5/thumbnails/45.jpg)
Contact• For questions about this audio conference please contact Dr. George
Wittenberg at [email protected]• For any questions about the monthly GRECC Audio Conference Series
please contact Tim Foley at [email protected] or call (734) 222-4328• To evaluate this conference for CE credit please obtain a ‘Satellite
Registration’ form and a ‘Faculty Evaluation’ form from the Satellite Coordinator at you facility. The forms must be mailed to EES within 2 weeks of the broadcast